AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03258164 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Lipofilling
Description: Non-ASC enriched fat grafts
Study NCT03451162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHES0815A
Description: DHES0815A will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle.
Study NCT01488487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 7.5 mg administered daily for 28 days per cycle until disease progression or unacceptable toxicity.
Study NCT01488487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: Monthly (every 28 days) intramuscular injection of long-acting pasireotide (pasireotide LAR 60 mg) repeated on day 1 of every 28 day cycle until disease progression or unacceptable toxicity.
Study NCT03936582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment
Description: information already included in arm/group descriptions
Study NCT03723642 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: VOC 15min
Description: Volatile organic compound sampling (2 samples within 5 minutes) 15 minutes after skin incision.
Study NCT03723642 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: VOC 30min
Description: Volatile organic compound sampling (2 samples within 5 minutes) 30 minutes after skin incision.
Study NCT03723642 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: VOC 45min
Description: Volatile organic compound sampling (2 samples within 5 minutes) 45 minutes after skin incision.
Study NCT03936582 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment
Description: information already included in arm/group descriptions
Study NCT03952429 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti Alcohol App with Active Cognitive Bias
Description: The active version includes an active form of cognitive bias modification, i.e. the user has to avoid alcohol stimuli 90% of the time, while they approach soft drinks 90% of the time.
Study NCT03952429 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Cognitive Bias Modification
Description: The control version includes an placebo form of cognitive bias modification, i.e. the users avoid and approach alcohol and softdrink stimuli for an equal number of trials.
Study NCT03025386 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: logatoms test
Description: A forced choice test will evaluate the discrimination of the most confusing logatoms in the cochlear implant users, and representative of the French language.
Study NCT03025386 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electroencephalography
Description: Mesure of the mismatch negativity wave
Study NCT04213430 — intervention group
Intervention type: OTHER
Intervention: diagnostic
Description: Training dataset was used to train the deep learning model, which was validated and tested by other two datasets.
Study NCT03904355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: Gonadotropin stimulation of follicular growth
Study NCT03904355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human chorionic gonadotropin
Description: HCG triggering of ovulation
Study NCT03904355 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ovum pick up
Description: 34 to 36 hours after oocyte retrieval
Study NCT03904355 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer
Description: Transfer of 2 grade 1 embryo on day 2,3 or 5 from oocyte retrieval
Study NCT03718078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Confocal Laser Endomicroscopy
Description: The study is divided in two parts. For the two parts, patients will receive an intravenous injection of indocyanine green:~1. Ex vivo study~   - Images/sequences of normal and abnormal hepatic tissues and surgical margins will be acquired on surgical specimens~2. In vivo study - Intra-operative pCLE imaging will be performed on hepatic masses and surgical margins
Study NCT02139787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radio Story
Study NCT02139787 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control -listened to a brochure
Study NCT00402597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban/Placebo
Description: 1 rivaroxaban tablet once daily (and 1 placebo tablet once daily) for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
Study NCT00402597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo tablet twice daily for 6 months.
Study NCT00402597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: 1 rivaroxaban tablet twice daily for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
Study NCT00264953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adriamycin
Study NCT00264953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Study NCT00264953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Study NCT00264953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Study NCT00264953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinblastine
Study NCT00264953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Study NCT00264953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTIC
Study NCT00264953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTIC
Study NCT00264953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT00264953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procarbazine
Study NCT00264953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT00264953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Study NCT00264953 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: 20 or 30Gy IF-RT
Study NCT00264953 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 20 or 30Gy IF-RT
Study NCT02152657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell transplantation
Description: Mesenchymal stem cell transplantation through percutaneous injection.
Study NCT03741569 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transabdominal Fetal Heart Rate
Description: Doppler, ECG and acoustic sensors will be placed on the mother's abdomen to capture the heart rate of the fetus and mother as well as uterine contractions.~For each of the participants, we will make two 15-minute recordings: one with conventional ECG electrodes and one with ECG textile electrodes
Study NCT00052182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EP HIV-1090
Study NCT02424513 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [89Zr]Df-IAB2M
Description: A single intravenous infusion of 2.5 mCi of \[89Zr\]Df-IAB2M in a mass dose of 10 mg.
Study NCT02972125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM) tablet
Description: Treatment A: Single dose of Lacosamide (LCM) 100 mg tablet
Study NCT02972125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM) dry syrup
Description: Treatment B: Single dose of Lacosamide (LCM) 100 mg given as dry syrup
Study NCT00298090 — intervention group
Intervention type: DEVICE
Intervention: StO2 monitoring
Description: placement of the StO2 device/ external noninvasive
Study NCT03316625 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Bone densitometry measurement
Description: Bone Densitometry and measurement of body composition
Study NCT03463967 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Lycopene-enriched tomato juice
Description: Energy-restricted diet supplemented with Lycopene-enriched tomato juice
Study NCT03463967 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lycopene-enriched tomato juice
Description: Energy-restricted diet supplemented with Lycopene-enriched tomato juice
Study NCT03463967 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Energy-restricted diet
Study NCT03463967 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Energy-restricted diet
Study NCT00938860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporin (Neoral)
Description: Neoral capsules bid, Doses were to be adjusted as necessary to achieve and maintain recommended C0 (monitoring of trough levels) or C2 concentration 2 hours post dosing) target ranges
Study NCT00938860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus (Prograf)
Description: Tacrolimus capsules bid, doses were adjusted as necessary to achieve and maintain recommended C0 target ranges.
Study NCT02288533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real-tDCS
Description: Participants will receive tDCS over the primary motor cortex bilaterally (M1). The excitability-enhancing anode electrode (saline-soaked sponge electrode - 16cm2) will be placed over the primary motor cortex, C3 and C4 (10/20 international EEG system). The excitability-diminishing cathode electrode will be placed over the supraorbital area. We will use the following stimulation parameters: intensity of 2 milliampere and for 40 minutes (10 consecutive sessions).
Study NCT01046890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Echinacea
Description: darunavir/ritonavir 600/100 mg + root of Echinacea purpurea 500 mg every 6 hours
Study NCT01098565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study device HFR0001
Description: Study device will be tested for up to 2 hours prior to chronic device implant.
Study NCT03322787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFO
Description: Training will be done using the HFO device. Air-flow will set at the highest value tolerated by the patients, until a maximum value of 60 l/min permitted and FiO2 set during the run-in. The HFO will be administered using the AIRVO2® (Fisher\&Paykel- NewZealand). Afterwards, the oxygen flow provided into the system will be progressively increased until the pre-fixed FiO2 will be reached, as displayed by the AIRVO2 monitor.
Study NCT02241954 — intervention group
Intervention type: DEVICE
Intervention: Synthes VEPTR (Vertical Expandable Prosthetic Titanium Rib)
Study NCT00370409 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Cryotherapy of both sides of sclerotomy sites was done for 6 seconds after complition of operation.
Study NCT00370409 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cryotherapy
Description: Cryotherapy of both sides of sclerotomy sites was done for 6 seconds after complition of operation.
Study NCT02623153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: oxaliplatin 130 mg/m2
Study NCT02623153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: oxaliplatin 130 mg/m2
Study NCT02623153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: capecitabine of 1000 mg/m2
Study NCT02623153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S1 of 40 mg/m2
Study NCT02623153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: docetaxel 40 mg/m2
Study NCT04579627 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: A single survey questionnaire to staff to report their demographics and facial hair styles between January and April 2020
Study NCT00912691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM-AT
Description: Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
Study NCT00512460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 744
Description: 4.8 mg/m\^2 by vein Over 2 Hours On Days 1-3.
Study NCT01055379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline
Description: 1 mg/day for 12 weeks; orally
Study NCT01055379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily for 12 weeks; orally
Study NCT00697879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHR-3996
Description: Once daily oral ingestion of capsules (5, 10, 20 or 40 mg), dose depending on cohort, treatment cycle of 28 days
Study NCT00639353 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A toric soft contact lens
Description: contact lens
Study NCT00639353 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A sphere soft contact lens
Description: contact lens
Study NCT00610467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Disease Group
Description: Participants will received the following agents before their imaging are taken MRI contrast agent (0.1 mmol/kg) optical contrast agent ICG (0.5 mg/kg)
Study NCT00610467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Participants will received the following agents before their imaging are taken MRI contrast agent (0.1 mmol/kg) optical contrast agent ICG (0.5 mg/kg)
Study NCT02697292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Immunoglobulin
Description: GAMUNEX-C is a clear a ready-to-use sterile solution of human immune globulin protein for intravenous administration. Dose will be determined based on ideal wt. with not to exceed 80 grams. Subjects will receive 0.5g/kg daily for 1 day \[week 1 day 1\], then will receive 1g/kg not exceeding 80 grams daily for 1 day \[week 1 day 2\]. Then once every 2 weeks subjects will receive 0.6g/kg IVIG for 4 weeks \[week 3 and 5\] for 2 infusions.
Study NCT02697292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Immunoglobulin
Description: GAMUNEX-C is a clear a ready-to-use sterile solution of human immune globulin protein for intravenous administration. Dose will be determined based on ideal wt. with not to exceed 80 grams. Subjects will receive 0.5g/kg daily for 1 day \[week 1 day 1\], then will receive 1g/kg not exceeding 80 grams daily for 1 day \[week 1 day 2\]. Then once every 2 weeks subjects will receive 0.6g/kg IVIG for 4 weeks \[week 3 and 5\] for 2 infusions.
Study NCT02697292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. Dose will be determined based on ideal wt. with not to exceed 80 grams. Dose will be determined based on ideal wt. with not to exceed 80 grams. Subjects will receive 0.5g/kg daily for 1 day \[week 1 day 1\], then will receive 1g/kg not exceeding 80 grams daily for 1 day \[week 1 day 2\]. Then once every 2 weeks subjects will receive 0.6g/kg for 4 weeks \[week 3 and 5\] for 2 infusions.
Study NCT02697292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. Subjects will receive 500 ml normal saline before and after the higher dose infusion of 1g/kg
Study NCT02697292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. Subjects will receive 500 ml normal saline before and after the higher dose infusion of 1g/kg
Study NCT02094755 — intervention group
Intervention type: OTHER
Intervention: Blood draw only
Description: Blood draw only
Study NCT01251731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5501
Description: Treatment Group 1: 10mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 40mg E5501 in Treatment Period 2, followed by a single dose of 80mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose reatment Period.
Study NCT01251731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5501
Description: Treatment Group 2: 40 mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 80mg E5501 in Treatment Period 2, followed by a single dose of 10mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose Treatment Period.
Study NCT01251731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5501
Description: Treatment Group 3: 80mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 10mg E5501 in Treatment Period 2, followed by a single dose of 40mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose Treatment Period.
Study NCT01251731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5501
Description: Treatment Group 4: A single dose of matching placebo in each of the three Single Dose Treatment Periods and in the Multiple Dose Treatment Period
Study NCT04651075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music listening
Description: The music selected by the participants was played to the music listening group.
Study NCT04651075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: individual training
Description: Individual training group was trained on coronary angiography.
Study NCT01063660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: 14 g/m²/d day -6 to -4
Study NCT03034629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short-term aerobic exercise
Description: One bout of moderate intensity exercise (75% of maximal predicated heart rate).
Study NCT03433248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMPA/LINA 10/5 mg QD (n=22)
Description: Once daily treatment with oral empagliflozin (Jardiance) 10 mg Once daily treatment with oral linagliptin (Tradjenta) 5 mg
Study NCT03433248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LINA/EMPA 5/10 mg QD (N=22)
Description: Once daily treatment with oral linagliptin (Tradjenta) 5 mg Once daily treatment with oral empagliflozin (Jardiance) 10 mg
Study NCT03433248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide 30 mg QD/BID (N=22)
Description: Once daily or twice daily treatment with oral glicazide MR 30mg
Study NCT03160651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone or placebo
Description: Patients will receive 28 days of methylprednisolone 32 mg/day
Study NCT03160651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone or placebo
Description: Patients will receive 28 days of methylprednisolone 32 mg/day
Study NCT03723642 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Final VOC
Description: Volatile organic compound sampling (2 samples within 5 minutes) within 5 minutes after skin closure.
Study NCT04393454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus 2mg Tablet
Description: Sirolimus (oral) will be started at 2 mg daily. Sirolimus dosing will be titrated to meet serum trough levels of >8 ng/ml, assayed at 7 days after starting a new dose, by chromatography/mass spectrometry. Once adequate serum levels are met (≥8 ng/ml), the same dosing will be continued until progression of disease as evidenced by imaging, or unacceptable toxicity.
Study NCT02987712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thromboelastography based protocol
Description: patients will be treated according to a new thromboelastography based protocol
Study NCT01224145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5x5cm bupivacaine collagen sponges
Study NCT02000206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study NCT02000206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Study NCT02000206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfentanil
Study NCT02119377 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Study NCT02211846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: oral
Study NCT01334450 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS , H2-coil
Description: Trans cranial magnetic stimulation with H2-coil
Study NCT01334450 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS , H2-coil
Description: Trans cranial magnetic stimulation with H2-coil
Study NCT01264796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: culturally tailored diabetes education
Description: lifestyle modification group education
Study NCT03843814 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: APT MRI
Study NCT03690297 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Linked Color Imaging
Description: Use of narrow band imaging with LCI for colon inspection during both insertion and withdrawal phase of colonoscopy
Study NCT03690297 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Linked Color Imaging
Description: Use of narrow band imaging with LCI for colon inspection during both insertion and withdrawal phase of colonoscopy
Study NCT04220307 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104
Description: Subjects will receive AK104 by intravenous administration